Lonapegsomatropin
Clinical data
Trade namesSkytrofa
Other namesLonapegsomatropin-tcgd; rhGH-PEG; ACP-011; ΤransConPEG hGh; WHO-10598
License data
Routes of
administration
Subcutaneous injection
Drug classGrowth hormone receptor agonist
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
PubChem SID
DrugBank
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC1051H1627N269O317S9[C2H4O]4n

Lonapegsomatropin, sold under the brand name Skytrofa, is a human growth hormone used for the treatment of growth hormone deficiency.[1] Lonapegsomatropin is a prodrug of somatropin.[1]

Lonapegsomatropin was approved for medical use in the United States in August 2021.[1][2][4]

Medical uses

Lonapegsomatropin is a growth hormone therapy indicated to treat growth hormone deficiency.[1][3]

References

  1. ^ a b c d e "Skytrofa- lonapegsomatropin-tcgd injection, powder, lyophilized, for solution". DailyMed. Retrieved 30 September 2021.
  2. ^ a b "Skytrofa: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 25 August 2021.
  3. ^ a b "Lonapegsomatropin Ascendis Pharma EPAR". European Medicines Agency. 10 November 2021. Retrieved 16 March 2022.
  4. ^ "Ascendis Pharma A/S Announces U.S. Food and Drug Administration Approval of Skytrofa (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency". Ascendis Pharma (Press release). 25 August 2021. Retrieved 25 August 2021.

Further reading